0001127602-23-006590.txt : 20230222
0001127602-23-006590.hdr.sgml : 20230222
20230222210226
ACCESSION NUMBER: 0001127602-23-006590
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230217
FILED AS OF DATE: 20230222
DATE AS OF CHANGE: 20230222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Halpin Michael
CENTRAL INDEX KEY: 0001778858
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35280
FILM NUMBER: 23655651
MAIL ADDRESS:
STREET 1: C/O VERICEL CORPORATION
STREET 2: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vericel Corp
CENTRAL INDEX KEY: 0000887359
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943096597
STATE OF INCORPORATION: MI
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 7349305555
MAIL ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC
DATE OF NAME CHANGE: 19960428
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2023-02-17
0000887359
Vericel Corp
VCEL
0001778858
Halpin Michael
C/O VERICEL CORPORATION
64 SIDNEY STREET
CAMBRIDGE
MA
02139
1
Chief Operating Officer
Common Stock
2023-02-18
4
M
0
2813
0
A
16096
D
Common Stock
2023-02-18
4
F
0
1332
29.82
D
14764
D
Common Stock
2023-02-19
4
M
0
3825
0
A
18589
D
Common Stock
2023-02-19
4
F
0
1868
29.82
D
16721
D
Stock Option
(Right to Buy)
29.82
2023-02-17
4
A
0
3282
0
A
2033-02-17
Common Stock
3282
3282
D
Stock Option
(Right to Buy)
29.82
2023-02-17
4
A
0
49218
0
A
2033-02-17
Common Stock
49218
49218
D
Restricted Stock Unit
2023-02-17
4
A
0
21000
0
A
Common Stock
21000
21000
D
Restricted Stock Unit
2023-02-18
4
M
0
2813
D
Common Stock
2813
12487
D
Restricted Stock Unit
2023-02-19
4
M
0
3825
D
Common Stock
3825
4613
D
The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual
installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively.
These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in
annual installments on February 19, 2024 and February 19, 2025.
These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.
Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 17, 2024. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively.
No expiration date for this type of award.
The Fair Market Value of the vested derivative securities is $29.82 per share.
/s/ Sean Flynn, as Attorney-in-Fact for Michael Halpin
2023-02-22